Author:
Li Junyang,Liu Hongyi,Xing Biao,Yu Yanzhe,Wang Hui,Chen Gong,Gu Bing,Zhang Guofeng,Wei Dong,Gu Peiyuan,Li Meng,Hu Weixing
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Neurology (clinical),Neurology,Oncology
Reference34 articles.
1. Ranza E, Mazzini G, Facoetti A, Nano R (2010) In vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 96:349–357. doi: 10.1007/s11060-009-9975-4
2. Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M (2011) Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol 103:585–593. doi: 10.1007/s11060-010-0423-2
3. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS (2011) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. doi: 10.1007/s11060-011-0722-2
4. Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS (2011) Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. doi: 10.1007/s11060-011-0631-4
5. Davis BB, Liu JY, Tancredi DJ, Wang L, Simon SI, Hammock BD, Pinkerton KE (2011) The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment. Biochem Biophys Res Commun 410:494–500. doi: 10.1016/j.bbrc.2011.06.008
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献